Modified Synthesis of NOP Receptor Antagonist SB612111

Abstract

SB612111 [(5S,7S)-7-{[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl}-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ol] is a potent and selective antagonist of the nociception/orphanin FQ peptide (NOP) receptor. In the process of synthesizing cis-SB612111 to support ongoing animal studies, several key steps of the published syntheses in the patent literature proceeded in low yields in our hands, particularly in the route to the key intermediate 4-(2,6-dichlorophenyl)piperidine, the reduction of 7-[4-(2,6-dichlorophenyl)piperidine-1-carbonyl]-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one, the formation of (±)-6-methyl-12-oxatricyclo[8.2.1.0^2,7]trideca-2,4,6-trien-11-one, and the final reductive amination between (±)-6-methyl-12-oxatricyclo[8.2.1.0^2,7]trideca-2,4,6-trien-11-ol and 4-(2,6-dichlorophenyl)piperidine in the diastereoselective synthesis. We have thus explored various reaction conditions and successfully improved the yields for the necessary synthetic steps. We herein report our modified synthesis of SB612111 as the cis-diastereomers.

Key words

NOP - antagonist - modified synthesis - SB612111

• References

• 1 Bunzow JR, Saez C, Mortrud M, Bouvier C, Williams JT, Low M, Grandy DK. FEBS Lett. 1994; 347: 284
• 2 Fukuda K, Kato S, Mori K, Nishi M, Takeshima H, Iwabe N, Miyata T, Houtani T, Sugimoto T. FEBS Lett. 1994; 343: 42
• 3 Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, Caput D, Vassart G, Meunier JC. FEBS Lett. 1994; 341: 33
• 4 Pan YX, Cheng J, Xu J, Rossi G, Jacobson E, Ryan-Moro J, Brooks AI, Dean GE, Standifer KM, Pasternak GW. Mol. Pharmacol. 1995; 47: 1180
• 5 Wang JB, Johnson PS, Imai Y, Persico AM, Ozenberger BA, Eppler CM, Uhl GR. FEBS Lett. 1994; 348: 75
• 6 Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, Davenport AP, Spedding M, Harmar AJ. Pharmacol. Rev. 2005; 57: 279
• 7 Henderson G, McKnight AT. Trends Pharmacol. Sci. 1997; 18: 293
• 8 Calo G, Guerrini R, Rizzi A, Salvadori S, Regoli D. Br. J. Pharmacol. 2000; 129: 1261
• 9 Civelli O, Nothacker HP, Reinscheid R. Crit. Rev. Neurobiol. 1998; 12: 163
• 10 Mogil JS, Pasternak GW. Pharmacol. Rev. 2001; 53: 381
• 11 Lambert DG. Nat. Rev. Drug Discovery 2008; 7: 694
• 12 Largent-Milnes TM, Vanderah TW. Expert Opin. Ther. Pat. 2010; 20: 291
• 13 Toledo MA, Pedregal C, Lafuente C, Diaz N, Martinez-Grau MA, Jimenez A, Benito A, Torrado A, Mateos C, Joshi EM, Kahl SD, Rash KS, Mudra DR, Barth VN, Shaw DB, McKinzie D, Witkin JM, Statnick MA. J. Med. Chem. 2014; 57: 3418
• 14 Kawamoto H, Ozaki S, Itoh Y, Miyaji M, Arai S, Nakashima H, Kato T, Ohta H, Iwasawa Y. J. Med. Chem. 1999; 42: 5061
• 15 Yamada H, Nakamoto H, Suzuki Y, Ito T, Aisaka K. Br. J. Pharmacol. 2002; 135: 323
• 16 Spagnolo B, Carra G, Fantin M, Fischetti C, Hebbes C, McDonald J, Barnes TA, Rizzi A, Trapella C, Fanton G, Morari M, Lambert DG, Regoli D, Calo G. J. Pharmacol. Exp. Ther. 2007; 321: 961
• 17 Rizzi A, Gavioli EC, Marzola G, Spagnolo B, Zucchini S, Ciccocioppo R, Trapella C, Regoli D, Calo G. J. Pharmacol. Exp. Ther. 2007; 321: 968
• 18 Zaratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P, Ronzoni S, Giardina GA, Scheideler MA. J. Pharmacol. Exp. Ther. 2004; 308: 454
• 19 Zaveri NT. J. Med. Chem. 2016; 59: 7011
• 20 Kiguchi N, Ding H, Ko MC. Adv. Pharmacol. 2016; 75: 217
• 21 Toll L, Bruchas MR, Calo G, Cox BM, Zaveri NT. Pharmacol. Rev. 2016; 68: 419
• 22 Barlocco D, Cignarella G, Giardina G, Grugni M, Ronzoni S. WO 2001083454, 2001
• 23 Trapella C, Fischetti C, Pela M, Lazzari I, Guerrini R, Calo G, Rizzi A, Camarda V, Lambert DG, McDonald J, Regoli D, Salvadori S. Bioorg. Med. Chem. 2009; 17: 5080
• 24 Palombi G, Ronzoni S. WO 2003040099, 2003
• 25 Rana S, Natarajan A. Org. Biomol. Chem. 2013; 11: 244
• 26 Tajbakhsh M, Hosseinzadeh R, Alinezhad H, Ghahari S, Heydari A, Khaksar S. Synthesis 2011; 490